Intech Investment Management LLC Trims Stock Position in Hologic, Inc. $HOLX

Intech Investment Management LLC lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 67.2% during the second quarter, HoldingsChannel.com reports. The fund owned 29,676 shares of the medical equipment provider’s stock after selling 60,915 shares during the period. Intech Investment Management LLC’s holdings in Hologic were worth $1,934,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Chung Wu Investment Group LLC purchased a new position in shares of Hologic during the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 273 shares in the last quarter. Zions Bancorporation National Association UT bought a new stake in Hologic during the first quarter valued at $34,000. Cromwell Holdings LLC boosted its stake in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 436 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in Hologic during the first quarter worth about $42,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. The trade was a 10.08% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by corporate insiders.

Hologic Stock Performance

NASDAQ:HOLX opened at $74.36 on Friday. The business has a 50 day moving average of $70.59 and a 200 day moving average of $66.30. The company has a market capitalization of $16.54 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 2.54 and a beta of 0.65. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $80.31. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the business earned $1.01 earnings per share. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent analyst reports. BNP Paribas Exane cut Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a report on Friday. JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 price objective on shares of Hologic in a research report on Wednesday, October 22nd. Argus raised their target price on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Friday, September 19th. BNP Paribas lowered shares of Hologic to a “neutral” rating and set a $79.00 target price for the company. in a research report on Friday. Finally, UBS Group increased their price target on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a report on Thursday, July 31st. Five equities research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $79.67.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.